Variation in Epidermal Morphology in Human Skin at Different Body Sites as Measured by Reflectance Confocal Microscopy by Robertson, Karen & Rees, Jonathan L.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variation in Epidermal Morphology in Human Skin at Different
Body Sites as Measured by Reflectance Confocal Microscopy
Citation for published version:
Robertson, K & Rees, JL 2010, 'Variation in Epidermal Morphology in Human Skin at Different Body Sites
as Measured by Reflectance Confocal Microscopy' Acta Dermato-Venereologica, vol 90, no. 4, pp. 368-
373., 10.2340/00015555-0875
Digital Object Identifier (DOI):
10.2340/00015555-0875
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher final version (usually the publisher pdf)
Published In:
Acta Dermato-Venereologica
Publisher Rights Statement:
© 2013 The Authors
© 2013 Acta Dermato-Venereologica
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 20. Feb. 2015
Acta Derm Venereol 93
COMMENTARY (see article on pp. 305–308)
Acta Derm Venereol 2013; 93: 259–260
© 2013 The Authors. doi: 10.2340/00015555-1567
Journal Compilation © 2013 Acta Dermato-Venereologica. ISSN 0001-5555
Frank Davidoff, the celebrated US physician, has a 
telling metaphor for medical competence: he likens it 
to Dark Matter, the material physicists think makes up 
most of the Universe, and about which we know so little 
(1). Clinical competence would, in this analogy, be the 
material that literally holds and binds clinical practice – 
our professional lives – together. How come we know 
so little about it? 
Literary fiction of course has plenty of bad doctors, 
but frequently they appear to be evil rather than merely 
clinically indifferent. Dr Watson, Sherlock Holmes’ 
fictional friend and narrator, is of course a general 
practitioner, and whereas we are unlikely to admire 
his intellectual abilities, we assume he is ‘sound’ in his 
professional life. This lack of judgement or curiosity 
about the abilities of individual physicians is how­
ever widespread in the real world too. Within the UK 
national health service (NHS), doctors, it sometimes 
seems, are viewed as interchangeable units, who possess 
skills defined at a lower bound in terms of training and 
certification, and who can be deployed as though they 
were machine tools in an industrial factory. Many of 
us think otherwise, believing that there is considerable 
variation in clinical competence (2). Hidden in plain 
sight perhaps, but present.
Different types of evidence attest to this variation 
in performance. Most doctors when they or their im­
mediate families are ill, choose who to consult with 
great care. Ever since the seminal work of Wennberg 
(3), we know that clinical decision­making by doctors 
is far from uniform or consistent, and that such diffe­
rences account for much of the variance in health care 
costs. We do not understand all the reasons for clinical 
heterogeneity – financial biases are likely to play a role 
– but from the patient’s perspective, medical advice is 
heavily dependent on who you consult. Finally, given 
what we know about expertise in general – in fields as 
diverse as musicianship, sport or academic ability – it 
would be bizarre if differences in ability were not the 
norm rather than the exception (4, 5).
It is the above arguments that make the paper from 
Ahnlide & Bjellerup (6) of Helsingborg Hospital and 
Lund University so welcome. The paper is a remarka­
bly straightforward and lucid piece of work – as good 
a reason for publication as any – in which the authors 
have set out to measure diagnostic accuracy for skin 
cancer in a particular hospital practice. Key to their 
design is that the study was prospectively designed and 
that doctors were obliged to provide only one clinical 
diagnosis. Why is this important?
The problem that bedevils retrospective studies on 
this topic is that the process of recording a diagnosis 
(let alone making a diagnosis) is not as straightforward 
as people often think. Imagine you see a patient with a 
pigmented lesion: you deem it clinically suspicious, but 
most likely to be a benign naevus, rather than a mela­
noma. You are 60% certain it is a benign melanocytic 
naevus, but 40% certain it could be a melanoma. What 
do you record as your diagnosis? Given a choice of only 
one diagnosis or ‘action point’, do you write naevus, or 
say ‘exclude melanoma’. Most of us, for good reason do 
not view errors in diagnosis as being symmetrical. If I 
scribble ‘naevus’ in the case notes, but the pathologist 
reports melanoma, my mental state differs from when 
the process is reversed – that is, when my clinical di­
agnosis of melanoma is contradicted by the pathologist 
saying it is a naevus. Our approach to diagnostic sensi­
tivity and specificity in the clinical workflow is heavily 
context dependent, but from a researcher’s perspective, 
this muddies the water. Forcing a uniform workflow 
process allows insights that would escape us if we just 
studied clinical case notes retrospectively.
Ahnlide & Bjellerup (6) interpret their results using 
two standard measures of performance: sensitivity and 
predictive value. To place their data in perspective how­
ever, we also need to think about specificity as well. 
Sensitivity of a test (here the clinician’s diagnosis) can be 
defined as the ratio of true positives to the total number 
of positives defined with a gold standard (pathology). 
The latter denominator will of course include the genuine 
diagnoses that were missed by the physician (i.e. clinical 
false negatives). In one sense sensitivity is about making 
certain you ‘rule in’ a particular diagnosis. An easy way to 
do this of course is to call every pigmented lesion you see 
a melanoma: the downside of this is that your specificity 
goes down, that is, you are increasingly bad at ‘ruling out 
melanomas’. But for a diagnosis that you cannot afford to 
miss, say, melanoma (rather than a basal cell carcinoma 
(BCC) for instance), a high sensitivity is a price surely 
worth paying for a low specificity. But notice the word 
‘price’: it comes at a cost.
Predictive value reflects different aspects of accuracy. 
It is simply the ratio of the correct clinical diagnosis 
to all the cases you label as having the same clinical 
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diagnosis, as arbitrated by the pathologist. The deno­
minator here includes the true positives identified by 
the clinician but also the false positives – those where 
the clinician has called it a melanoma but the lesion 
was a benign naevus on pathology (the reader will note 
I assume pathologists are infallible…). In one sense 
predictive value conforms to our everyday sense of 
‘how often we are right’. Its downside (as the authors 
remind us) is that it is heavily dependent on the pre­
valence of disease. An example that I use with clinical 
trainees highlights this. Imagine I sit in my office, and 
do not see any patients in the pigmented lesion clinic. 
Instead, knowing that say only 2% of referred patients 
have a melanoma, I diagnose every patient as ‘not being 
melanoma’. I am right 98% of the time and boast about 
my 98% diagnostic accuracy, all without having to put 
my coffee aside to visit the clinic. Of course, if the case 
mix alters my claims are seen for what they are. If the 
clinic now contains 50% of patients with melanoma, 
my accuracy would have dropped to 50% – and yet my 
behaviour has not changed. It is this aspect of predictive 
value that so often limits attempts to compare primary 
care and secondary care physicians. A GP can claim 
expertise in melanoma diagnosis because no patient of 
his has died of melanoma in the last 10 years. However 
examination of the incidence of melanoma in the UK, 
tells us that even a blind clinician could make the same 
argument for his or her clinical acumen.
Ahnlide & Bjellerup’s (6) findings are in one sense 
expected. We are better at diagnosing BCCs than 
squamous cell carcinomas, but that our sensitivity and 
predictive values for diagnosing melanomas are much 
lower (the inhabitants of Helsingborg in particular 
should remember however that this is a study based on 
a single diagnosis, not the decision whether to request 
a biopsy or not). What they also provide is interesting 
data on which way we makes errors between diagnostic 
categories.
I started this brief essay pointing out that we knew 
little about medical expertise (2). This situation is likely 
to change for at least two reasons. First, all that we know 
about the acquisition of any form of advanced skill, tells 
us that feedback on performance is critical. Without 
information on how we are doing, it is not possible to 
review progress and improve on our abilities. If you 
wish to perform – and in this sense medicine is about 
performance – you have to actively seek out ways to 
improve. Mere passive contemplation is not sufficient: 
data, and in particular structured data, is needed (5, 
7). Second, doctors need to be increasingly aware that 
others too are interested in performance. David Margolis 
writing in the Archives of Dermatology almost 15 years 
ago recalled that whereas his early career ran parallel 
to an explosion of basic bioscience discovery, as far as 
clinical practice was concerned “no change has been as 
dramatic as the changing landscape of who is primarily 
responsible for patient care and who pays the bill” (8). 
Competence is inextricably linked to health care costs 
and patient outcomes. Ahnlide & Bjellerup’s paper is 
worth reading: there is plenty more to come.
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